$1.83
2.73%
Downside
Day's Volatility :9.64%
Upside
7.11%
63.88%
Downside
52 Weeks Volatility :78.81%
Upside
41.35%
Period | Cardiol Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -24.07% | 0.0% |
6 Months | 12.27% | 0.0% |
1 Year | 88.66% | 0.0% |
3 Years | -56.94% | -22.3% |
Market Capitalization | 128.9M |
Book Value | $0.22 |
Earnings Per Share (EPS) | -0.33 |
Wall Street Target Price | 9.01 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -54.15% |
Return On Equity TTM | -108.44% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 78.8K |
EBITDA | -31.7M |
Diluted Eps TTM | -0.33 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.33 |
EPS Estimate Next Year | -0.31 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Next Quarter | -0.09 |
What analysts predicted
Upside of 392.35%
Sell
Neutral
Buy
Cardiol Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cardiol Therapeutics Inc | -4.69% | 12.27% | 88.66% | -56.94% | -23.43% |
![]() Neurocrine Biosciences Inc. | -16.62% | -11.2% | 10.78% | 28.21% | 20.17% |
![]() Haleon Plc Spon Ads | 7.49% | 20.82% | 28.48% | 39.41% | 39.41% |
![]() Zoetis Inc. | 2.41% | 4.25% | 0.77% | -8.94% | 49.4% |
![]() Viatris Inc. | -0.79% | -8.6% | 12.7% | -23.12% | -31.03% |
![]() Catalent, Inc. | 0.82% | 6.48% | 22.57% | -57.47% | 16.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cardiol Therapeutics Inc | NA | NA | NA | -0.33 | -1.08 | -0.54 | NA | 0.22 |
![]() Neurocrine Biosciences Inc. | 36.53 | 36.53 | 0.27 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
![]() Haleon Plc Spon Ads | 33.32 | 33.32 | 1.47 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
![]() Zoetis Inc. | 36.6 | 36.6 | 2.61 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
![]() Viatris Inc. | 224.4 | NA | 0.07 | 2.68 | -0.03 | 0.03 | 0.04 | 16.36 |
![]() Catalent, Inc. | 211.02 | NA | 2.87 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cardiol Therapeutics Inc | Buy | $128.9M | -23.43% | NA | 0.0% |
![]() Neurocrine Biosciences Inc. | Buy | $12.2B | 20.17% | 36.53 | 16.0% |
![]() Haleon Plc Spon Ads | Buy | $47.1B | 39.41% | 33.32 | 9.66% |
![]() Zoetis Inc. | Buy | $85.7B | 49.4% | 36.6 | 26.29% |
![]() Viatris Inc. | Hold | $13.5B | -31.03% | 224.4 | -4.24% |
![]() Catalent, Inc. | Hold | $10.9B | 16.16% | 211.02 | -23.81% |
Tejara Capital Ltd
AdvisorShares Investments, LLC
Mmcap International Inc. Spc
Lion Street Advisors, LLC
CAMBRIDGE Invest RESEARCH ADVISORS, INC.
We Are One Seven, LLC
cardiol therapeutics is a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure. heart failure is a chronic condition that affects more than 26 million people globally. over five million adults in the u.s. suffer from heart failure, and it remains a leading cause of death and hospitalization with associated healthcare costs exceeding $30 billion annually. people with heart failure experience shortness of breath, fatigue, rapid heart rate, edema, reduced exercise capacity and a marked reduction in quality of life. approximately half of all heart failure patients have heart failure with preserved ejection fraction (hfpef), which is often associated with diabetes, obesity and high blood pressure and for which there have been no new therapies developed in over 20 years. cardiol is developing ctx01, a proprietary nanoformulation of pharmaceutical cannabidiol for the treatment of hfpef. cannabidiol has
Organization | Cardiol Therapeutics Inc |
Employees | 0 |
CEO | Mr. David G. Elsley MBA |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$1.83
-4.19%
Keyarch Acquisition Corp
$1.83
-4.19%
Connexa Sports Technologies Inc
$1.83
-4.19%
Us Value Etf
$1.83
-4.19%
First Wave Biopharma Inc
$1.83
-4.19%
Global X Msci Next Emerging
$1.83
-4.19%
Fat Projects Acquisition Corp
$1.83
-4.19%
Capital Link Global Fintech
$1.83
-4.19%
Applied Uv Inc
$1.83
-4.19%